May 2021: We have reinstated and amended recommendations 1.5.11 and 1.5.12 in line with updated MHRA safety advice on the risk of serious liver injury with ulipristal acetate (Esmya).
March 2020: In response to updated MHRA advice on the use of ulipristal acetate (Esmya), we amended recommendations 1.5.10, 1.5.13 and 1.5.17 and withdrew recommendations 1.5.11 and 1.5.12. Recommendations 1.5.13 and 1.5.27 are marked as [2018, amended 2020] or [2007, amended 2020].
March 2018: We added new recommendations on investigations for heavy menstrual bleeding (HMB) and management. These recommendations are marked as .
Some changes were made to recommendation wording without an evidence review. These recommendations are marked as [2007, amended 2018]. These changes were mainly for ease of reading and consistency, or to reflect current practice or drug safety advice.